Research Article

Discontinuation Rates of Tadalafil Alone and in Combination with α-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis

Qiang Chen (1), Yinjun Mao (2), Huiliang Zhou (1), and Songxi Tang (1)

1Department of Andrology & Sexual Medicine, First Affiliated Hospital of Fujian Medical University, Chazhong Road No. 20, Fuzhou 350005, Fujian, China
2Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Chazhong Road No. 20, Fuzhou 350005, Fujian, China

Correspondence should be addressed to Songxi Tang; drsxtang@fjmu.edu.cn

Received 23 August 2022; Revised 12 October 2022; Accepted 15 October 2022; Published 3 November 2022

Academic Editor: Qing Wang

Copyright © 2022 Qiang Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. We examined the discontinuation rates of tadalafil alone and in combination with α-blockers (ABs) for the treatment of male lower urinary tract symptoms (LUTS), with or without erectile dysfunction (ED).

Materials and Methods. We searched the EMBASE, PubMed, Web of Science, Scopus, Cochrane Library, and ClinicalTrials.gov databases for studies published until May 15, 2022. The discontinuation rates associated with LUTS medications were subsequently analyzed by meta-analysis. Results. Forty-four studies, including 1724 discontinued patients, were included. The combined discontinuation rate was 12.78% (95% confidence interval (CI) 9.89–15.98%), and the discontinuation rates because of adverse events and lack of efficacy were 4.56% (95% CI 3.39–5.90%) and 3.30% (95% CI 1.53–5.72%), respectively.

Conclusions. The discontinuation rate of tadalafil alone or in combination with ABs for LUTS with or without ED was relatively low and varied according to the study type. Patients receiving monotherapy or combination therapy were similarly likely to abandon treatment. Treatment with a fixed-dose combination was associated with better persistence than with a free-dose combination. These data may help guide clinicians in selecting drug regimens when making decisions. Factors associated with treatment withdrawal need to be determined through high-quality clinical studies to reduce the drug discontinuation rate, which will ultimately reduce healthcare costs and improve patient outcomes.

1. Introduction

Several preclinical and clinical trials have demonstrated a strong correlation between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) [1], several of which have also shown that LUTS caused by benign prostatic hyperplasia (BPH) is an independent risk factor for ED [1]. Treatment approaches aim to avoid BPH-related complications, stop BPH progression, and improve symptoms and quality of life. The currently available medical therapies for LUTS include 5a-reductase inhibitors (5ARIs), α-blockers (ABs), and their combination therapy (CT) [2, 3]. Although effective, these treatments can exert side effects associated with sexual dysfunction [4].

Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5i), has been shown to be effective in once-daily and/or on-demand treatment for ED, with proven efficacy in multiple controlled clinical trials, including those in LUTS patients with and without ED [5, 6]. Tadalafil acts directly on the micturition phases, not just penile erection, by increasing nitric oxide levels in the smooth muscle to relax the prostate and bladder neck [7, 8]. The efficacy of PDE5is in combination with ABs for remission of LUTS has also been assessed. Currently, research has shown this treatment to
have beneficial additive effects on both sexual function and LUTS compared to monotherapy [9]. Hence, the opportunity to treat LUTS with or without ED by using tadalafil alone or in combination with ABs may lead to new and increasingly tailored treatment strategies.

However, several clinical surveillance studies have suggested that the discontinuation rates of medical treatment for LUTS, including overactive bladder or BPH, are quite high [10, 11]. In these studies, dissatisfaction and therapy failure were identified as the main reasons for drug withdrawal. To our knowledge, longitudinal information regarding the use of tadalafil alone or in combination with ABs in patients with LUTS is limited. Thus, we performed this systematic review and meta-analysis to investigate the discontinuation rate of tadalafil alone or in combination with ABs in male LUTS patients with or without ED.

2. Materials and Methods

2.1. Study Protocol. This study protocol was registered on the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY, registration number: INPLASY202260105) [12].

2.2. Search Strategy. The English-language literature was systematically reviewed until May 15, 2022, in accordance with the criteria of the Preferred Reporting Project for Systematic Reviews and Meta-Analysis (PRISMA) [13]. The PRISMA checklist is provided in Table S1. The EMBASE, PubMed, Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov databases were searched to identify studies reporting the effects of tadalafil alone or in combination with ABs to treat LUTS patients with or without coexisting ED. We performed an extensive search using Medical Subject Headings (MeSH) terms and related keywords: “tadalafil,” “lower urinary tract symptoms,” “Cialis,” and “bladder overactive” (Table S2). Additionally, references in the retrieved articles were manually searched to attempt to identify any studies not found in the original literature search.

2.3. Study Selection. Based on the population, intervention, comparison, outcomes, and study design (PICOS) approach, the trials included in our study met the following criteria: (P) male patients with LUTS with or without ED; (I) consuming medication: tadalafil alone or in combination with ABs; (C) none; (O) evaluating the incidence of drug discontinuation: studies must report patients discontinuing medication, regardless of reasons; and (S) prospective, retrospective, observational, and randomized clinical trials (RCTs) were included. We placed no restrictions on the sample size, drug dose, or follow-up duration. We excluded any studies which were repeated publications, or those for which the original data for the literature could not be provided, or those for which the authors did not receive a response after contacting the authors. We further excluded any non-human studies, case series, case reports, commentaries, and reviews.

2.4. Study Outcomes. This study aimed to measure the discontinuation rate of the main treatment drug (tadalafil alone or in combination with ABs) for LUTS. Discontinuation was defined as the nonpersistence of the main treatment drug prescribed at the start of the first treatment, regardless of the reason. The discontinuation rate was calculated by dividing the number of patients who discontinued treatment by the total number of initial index patients. Further, the discontinuation rate due to adverse events (AEs) was defined to include only patients who discontinued treatment because of AEs in the numerator. Similarly, the discontinuation rate due to lack of efficacy was defined to include only patients who discontinued treatment because of drug inefficacy in the numerator.

2.5. Data Extraction and Quality Assessment. The authors CQ and M-Y separately extracted data from each included study and crosschecked the results after extraction. Any disagreements between reviewers regarding data extraction were resolved through consensus discussion with a third reviewer. The information extracted from the included studies was as follows: (1) publication date, (2) name of the first author, (3) country of study, (4) type of design, (5) drug regimen and dose received by the patient, (6) number of participants per drug regimen, (7) treatment period, and (8) data on total number of patients who discontinued treatment, discontinuation due to AEs, and no efficacy.

Bias assessments of observational studies were rated on the Newcastle-Ottawa Scale, whereas RCTs were evaluated using the Cochrane risk of bias assessment tool.

2.6. Statistical Analyses. The statistical software R version 4.0.3 (package “meta”) was used for all statistical analyses. Due to differences in the methodological and clinical perspectives in the included studies, we surmised that the heterogeneity among the included studies may be large. Hence, we used a random-effects model to obtain pooled estimates and a 95% confidence interval (CI) of the discontinuation rate, and the variance was stabilized by an arcsine transformation [14, 15]. Heterogeneity was assessed using Cochran’s value and $I^2$. The heterogeneity test was cut off at significant Cochran Q-values ($P < 0.1$) and $I^2 > 50\%$, as an $I^2$ value of 30–50% was suggested as a cutoff value for moderate heterogeneity [16]. A prediction interval (PI) for the proportion in a new study was calculated if the argument prediction and comb. random were TRUE [17].

A cumulative meta-analysis was conducted to determine whether the discontinuation rate stabilized with an increasing sample size. A sensitivity analysis was further performed to phase out each study to test the reliability of the discontinuation rate.

In addition, subgroup analyses were performed according to drug regimen (monotherapy or CT), study design (prospective observational study, retrospective observational study, or RCT), and combination form (fixed-dose combination (FDC) (5 mg tadalafil/0.4 mg tamsulosin or 5 mg tadalafil/0.2 mg tamsulosin) or free-dose combination (different doses of tadalafil + different doses of Abs)).
3. Results

3.1. Search Results and Study Characteristics. The initial literature search revealed 2361 studies, of which 44 comprising a total of 1724 discontinued patients were deemed eligible. The PRISMA literature selection flowchart is shown in Figure 1.

The included studies, published between 2007 and 2021, [5, 6, 18–59] included 11 prospective studies [27, 28, 35, 39–41, 43, 47, 50, 51, 58], 2 retrospective studies, [36, 37] and 31 RCTs. Thirty-four studies came from a single country, with Japan and Korea predominating, while the rest were multinational studies. Overall, 34 studies evaluated tadalafil monotherapy, 6 evaluated CT with ABs [30–36, 53], and 4 evaluated tadalafil monotherapy plus CT [31–33, 48]. One study used a combination of alfuzosin [48], 2 studies partially used a combination with alfuzosin or silodosin, [35, 53] 1 study used a combination with uroselective (alfuzosin, silodosin, or tamsulosin) and nonuroselective (doxazosin or terazosin) ABs, [54] and the rest used a combination with tamsulosin. The characteristics of the included studies are summarized in Table 1.

3.2. Quality Assessment. Tables S3 and S4 present a full summary of the risk of bias for the included studies. Of the 13 observational studies, seven (54%) were of high quality [35, 37, 39, 40, 43, 51, 58] and the rest were of moderate quality; 46% of the observational studies did not mention adjustment for confounders [27, 28, 36, 41, 47, 50]. The details of the 31 RCTs were as follows: (1) selection bias: 12 out of 31 studies reported the method of random sequence generation, [6, 23, 26, 31, 33, 34, 44–46, 49, 52, 55] while the others did not. Eight studies involved allocation concealment, [6, 23, 26, 33, 34, 46, 49, 53] while the remaining studies did not provide any information about allocation concealment; (2) performance and detection bias: 20 studies were double-blind, 2 were double-blind plus open-label, [25, 33] 1 study was single-blind, [32] and 5 did not apply any blinding [31, 42, 45, 48, 55], while the remaining studies did not provide any information on blinding; (3) attrition bias: all studies provided information on the dropout rate or on patients lost to follow-up; and (4) reporting and other bias: all studies had a sufficient follow-up time (>1 month) to detect changes in quality of life or AEs. As such, there was no significant reporting or other bias.

3.3. Discontinuation Rate. Figure 2 shows the discontinuation rate in each study and overall. The discontinuation rates in LUTS patients ranged from 2.16% to 48.24% in the 44 studies. The combined discontinuation rate was 12.78% (95% CI 9.89–15.98%), with a high heterogeneity ($I^2 = 97%$), and the $P$ was 0.48 to 37.77. The overall discontinuation rate due to AEs was 4.56% ((95% CI 3.39–5.90%), $I^2 = 81%$, $P$ (0.17–14.44), Figure 3(a)), whereas the discontinuation rate due to no efficacy was even lower (3.30% (95% CI 1.53–5.72%), $I^2 = 94%$, $P$ (0.01–17.53), Figure 3(b)).

3.4. Subgroup Analyses of Discontinuation Rate. The results of the subgroup analyses for the discontinuation rate in patients with LUTS are summarized in Table 2 and Figure S1. Among the different types of study designs, the discontinuation rate in retrospective observational studies was higher than in other study designs (46.82% (95% CI 40.70–52.99%)), followed by prospective observational studies (17.53% (95% CI 10.87–25.39%)), and RCTs (9.78% (95% CI 7.66–12.12%)).

Patients undergoing CT (12.87% (95% CI 6.59–20.86%)) were similarly likely to discontinue monotherapy treatment (12.16% (95% CI 9.20–15.46%)). In contrast, the rate of treatment discontinuation caused by AEs in patients receiving CT (6.43% (95% CI 2.72–11.59%)) was higher than that in patients receiving monotherapy (4.12% (95% CI 3.08–5.30%)).

The treatment discontinuation rate was lower with fixed-dose combination therapy (10.62% (95% CI 5.84–16.61%)) than with FDC (24.00% (95% CI 0.52–66.34%)). However, the opposite conclusion was reached when the only retrospective observational study (that of Ahn et al. [36]) was removed from the FDC (8.18% (95% CI 6.36–10.33%)) vs. free-dose combination (10.62% (95% CI 5.84–16.61%)) subgroup.

3.5. Cumulative Analysis of Discontinuation Rate. Cumulative meta-analysis results showed that, with an increase in sample size, point estimation tended to be stable and CI gradually decreased, indicating that the larger the sample size, the higher the accuracy of the results (Figure S2).

3.6. Sensitivity Analysis of Discontinuation Rate. When each study was sequentially excluded from the analysis, the sensitivity analysis results (12.08% to 13.14%) remained in good agreement with the discontinuation rate, indicating that the study results were robust (Figure S3).

4. Discussion

LUTS symptoms and ED severity tend to increase with age [60]. Hence, as with other chronic diseases, long-term use of LUTS and ED medications is important to improve the patient's symptoms and quality of life [61]. Although tadalafil alone and in combination with ABs has been proven to be effective and well tolerated in clinical studies, patient outcomes in clinical practice are not always consistent with research findings. One reason for this may be the relatively high rates of premature drug discontinuation [10]. This is the first report to investigate the discontinuation rate of tadalafil alone or in combination with ABs for the treatment of male LUTS with or without ED. The total discontinuation rate was 12.78%, of which the discontinuation rates due to AEs and ineffectiveness were 4.56% and 3.30%, respectively.

Overall, the discontinuation rates observed herein appear to be relatively low, despite the inclusion of observational studies and RCTs. Interestingly, the discontinuation rate was much higher in observational studies than in RCTs.
The lower discontinuation rate in clinical studies may be due to both better adherence to recommendations made in the clinical trial setting and increased patient motivation [33]. Additionally, in clinical trials, patients are closely observed and receive medication free of charge during the study period [62]. This can improve the incidence of drug persistence. In contrast, in real-world clinical practice, patients often pay for drugs, which may result in higher expectations for their efficacy as well as a decreased tolerance for side effects. Moreover, a previous study also showed that self-reported economic status was related to long-term medication persistence [63]. In this study, respondents were asked whether their household income was sufficient to meet their needs. Persistence was 30% higher among those who answered “sufficient” or “more than sufficient.” Knowledge of these factors has allowed more illuminating clinical research to be conducted in real-world practice settings; hence, the actual incidence of treatment discontinuation can be calculated more accurately. Nevertheless, it is inevitable that the discontinuation rate will be underestimated in retrospective studies. The reasons for this include that patients who were excluded due to unrecorded follow-up examinations could not be analyzed, and it is not possible to know whether they discontinued treatment or continued treatment at another hospital. In some cases, discontinuation data are obtained through prescription records or self-reports rather than independent audits of pill counts or other, more accurate, verification methods. Treatment persistence may be overestimated if patients fail to refill their prescriptions.

Even more interestingly, patients who were treated with CT or monotherapy had similar discontinuation rates (12.87% vs. 12.16%). These data contradict the results of prior research evaluating long-term treatment for LUTS, which showed a lower discontinuation rate for CT (doxazosin + finasteride) (18%) compared to doxazosin (27%) and finasteride (24%) monotherapy [64]. In addition, the discontinuation rates reported in our study were relatively lower than those calculated in this study. However, it is difficult to compare the two studies owing to the differences in drug regimens and study design (meta-analysis vs. prospective randomized study), and these differences should therefore be interpreted with caution. Notably, discontinuation of tadalafil or ABs was easier and more regulated than

---

**Figure 1:** PRISMA flow chart illustrating the study selection process.
Table 1: Baseline characteristics of the included trials.

| Study/Year       | Country                                              | Study design | Arm                      | Discontinuation (n) | Discontinuation due to AEs (n) | Discontinuation due to no efficacy (n) | Time of therapy (month) |
|------------------|-------------------------------------------------------|--------------|--------------------------|---------------------|-------------------------------|----------------------------------------|------------------------|
| McVary (2007)    | US RCT                                                | 5 mg tadalafl (N = 138) | 9                       | 4                    | 0                             | 0                       | 6                      |
|                  |                                                       | 20 mg tadalafl (N = 129) | 4                       | 1                    | 0                             | 0                       | 6                      |
| Roehrborn (2008) | 10 Countries¹ RCT                                     | 2.5 mg tadalafl (N = 209) | 27                      | 4                    | 1                             | 0                       | 12                     |
|                  |                                                       | 5 mg tadalafl (N = 212) | 30                      | 12                   | 2                             | 0                       | 12                     |
|                  |                                                       | 10 mg tadalafl (N = 216) | 41                      | 11                   | 1                             | 0                       | 12                     |
|                  |                                                       | 20 mg tadalafl (N = 209) | 47                      | 14                   | 2                             | 0                       | 12                     |
| Porst (2009)     | 10 Countries¹ RCT                                     | 2.5 mg tadalafl (N = 117) | 16                      | 3                    | 0                             | 1                       | 12                     |
|                  |                                                       | 5 mg tadalafl (N = 113) | 16                      | 6                    | 1                             | 0                       | 12                     |
|                  |                                                       | 10 mg tadalafl (N = 120) | 23                      | 6                    | 0                             | 2                       | 12                     |
|                  |                                                       | 20 mg tadalafl (N = 116) | 27                      | 6                    | 2                             | 0                       | 12                     |
| Porst (2011)     | US, Argentina, Germany, Italy, and Mexico RCT         | 5 mg tadalafl (N = 161) | 13                      | 3                    | 1                             | 12                      |                        |
| Kim (2011)       | Korea RCT                                             | 5 mg tadalafl (N = 51)  | 3                       | 2                    | —                             | 12                      |                        |
| Oelke (2012)     | 10 Countries² RCT                                     | 5 mg tadalafl (N = 171) | 15                      | 2                    | 0                             | 12                      |                        |
| Egerdie (2012)   | 9 Countries¹ RCT                                      | 2.5 mg tadalafl (N = 198) | 26                      | 3                    | 1                             | 3                       | 12                     |
|                  |                                                       | 5 mg tadalafl (N = 208) | 24                      | 6                    | 3                             | 12                      |                        |
| Yokoyama (2012)  | Japan, Korea, and Taiwan                              | 2.5 mg tadalafl (N = 151) | 15                      | 5                    | 1                             | 12                      |                        |
|                  |                                                       | 5 mg tadalafl (N = 155) | 18                      | 7                    | —                             | 12                      |                        |
| Takeda (2012)    | Japan RCT OLE³                                       | 2.5 mg tadalafl (N = 142) | 7                       | 4                    | —                             | 12                      |                        |
|                  |                                                       | 5 mg tadalafl (N = 140) | 12                      | 5                    | 2                             | 12                      |                        |
|                  |                                                       | 5 mg tadalafl (N = 394) | 71                      | 35                   | 5                             | 42                      |                        |
| Takeda (2014)    | Japan and Korea RCT                                   | 5 mg tadalafl (N = 306) | 14                      | 4                    | —                             | 12                      |                        |
| Yang (2019)      | Korean RCT                                             | 5 mg tadalafl (N = 51)  | 7                       | 2                    | —                             | 12                      |                        |
| Matsukawa (2019) | Japan Prospective                                     | 5 mg tadalafl (N = 105) | 11                      | 5                    | —                             | 48                      |                        |
| Bechara (2014)   | Argentina Prospective                                 | 5 mg tadalafl (N = 67)  | 6                       | 1                    | —                             | 6                       |                        |
| Zhang (2018)     | Mainland China, Taiwan and Korea RCT                  | 5 mg tadalafl (N = 363) | 17                      | 6                    | —                             | 12                      |                        |
| Study/Year         | Country   | Study design | Arm                                      | Discontinuation (n) | Discontinuation due to AEs (n) | Discontinuation due to no efficacy (n) | Time of therapy (month) |
|-------------------|-----------|--------------|------------------------------------------|---------------------|-------------------------------|------------------------------------------|-------------------------|
| Bechara (2008) [30] | Argentina | RCT          | 20 mg tadalafil + 0.4 mg tamsulosin (N = 15) | 1                   | 1                             | —                                        | 6                       |
| Singh (2014) [31]  | India     | RCT          | 10 mg tadalafil (N = 44)                   | 4                   | 4                             | —                                        | 12                      |
|                   |           |              | 10 mg tadalafil + 0.4 mg tamsulosin (N = 44) | 2                   | 1                             | —                                        | —                       |
| Karami (2016) [32] | Iran      | RCT          | 20 mg tadalafil (N = 61)                   | 1                   | 1                             | —                                        | 12                      |
|                   |           |              | 20 mg tadalafil + 0.4 mg tamsulosin (N = 61) | 3                   | 3                             | —                                        | —                       |
| Kim (2017) [33]    | Korean    | RCT OLE³     | 5 mg tadalafil (N = 171)                  | 18                  | —                             | —                                        | 12                      |
|                   |           |              | 5 mg tadalafil + 0.2 mg tamsulosin (N = 170) | 18                  | —                             | —                                        | 12                      |
|                   |           |              | 5 mg tadalafil + 0.4 mg tamsulosin (N = 169) | 31                  | —                             | —                                        | —                       |
|                   |           |              | 5 mg tadalafil + 0.4 mg tamsulosin (N = 443) | 15                  | —                             | —                                        | —                       |
| Nagasubramanian (2020) [34] | India | RCT          | 5 mg tadalafil + 0.4 mg tamsulosin (N = 69) | 14                  | 4                             | —                                        | 12                      |
| Lee (2012) [35]    | Korea     | Prospective  | Tadalafil + ABs (tamsulosin or alfuzosin) (N = 158) | 39                  | 2                             | 12                                       | 12                      |
| Ahn (2020) [36]    | Korea     | Retrospective| 5 mg tadalafil + 0.4 mg tamsulosin (N = 97) | 44                  | 28                            | 10                                       | 24                      |
| Wada (2020) [37]   | Japan     | Retrospective| Tadalafil (N = 155)                       | 74                  | 21                            | 31                                       | 48                      |
| Pinggera (2014) [38] | US, Austria, and Italy | RCT | 5 mg tadalafil (N = 47)                  | 8                   | 4                             | —                                        | 8                       |
| Takahashi (2020) [39] | Japan | Prospective  | 5 mg tadalafil (N = 31)                   | 9                   | 8                             | —                                        | 12                      |
| Matsukawa (2020) [40] | Japan | Prospective  | 5 mg tadalafil (N = 80)                   | 11                  | 4                             | —                                        | 48                      |
| Amano (2017) [41]  | Japan     | Prospective  | 5 mg tadalafil (N = 81)                   | 4                   | 1                             | 1                                        | 24                      |
| Donatucci (2010) [42] | US and Canada | RCT | 5 mg tadalafil (N = 427)                  | 128                 | 22                            | 15                                       | 48                      |
| Choi (2014) [43]   | Korea     | Prospective  | 5 mg tadalafil (N = 90)                   | 17                  | 3                             | 5                                        | 12                      |
that of 5ARIs or antimuscarinics (AMs). In fact, tadalafil and ABs both show rapid activity and can be easily and effectively retaken [26, 65].

However, compelling evidence in the literature suggests that treatment persistence is inversely correlated with the complexity of medication regimens. With this in mind, so-called FDC drugs (compilation of two or more drugs in a single tablet/pill) have been developed to treat multiple clinical conditions (e.g., hyperlipidemia and hypertension) or one disease (e.g., asthma, diabetes mellitus) in a complementary manner [66]. When only RCTs were included, a single tablet in an FDC regimen has a lower discontinuation rate than the use of two tablets in the free-dose combination for the treatment of LUTS. Our findings are consistent with the results from two retrospective observational cohorts of men with LUTS treated with AM + AB in Spain and the Netherlands, showing FDC had higher persistence rates than free-dose combinations [67, 68]. This advantage has been extensively demonstrated in other pathologies. A meta-analysis of hypertension data published

---

**Table 1: Continued.**

| Study/Year | Country | Study design  | Arm                          | Discontinuation (n) | Discontinuation due to AEs (n) | Discontinuation due to no efficacy (n) | Time of therapy (month) |
|------------|---------|---------------|------------------------------|---------------------|-------------------------------|---------------------------------------|-------------------------|
| Kang (2012) [44] | Korea | RCT           | 5 mg tadalafil (N = 84)      | 18                  | 3                             | 1                                     | 12                      |
| Yoshida (2017) [45] | Japan | RCT           | 5 mg tadalafil (N = 139)     | 3                   | 1                             | —                                     | 8                      |
| Urakami (2018) [46] | Japan | RCT           | 5 mg tadalafil (N = 38)      | 7                   | 7                             | —                                     | 12                     |
| Takahashi (2016) [47] | Japan | Prospective  | 5 mg tadalafil (N = 35)      | 8                   | 4                             | —                                     | 12                     |
| Liguori (2009) [48] | Italy | RCT           | 20 mg tadalafil (N = 21)     | 2                   | 2                             | 2                                     | 12                     |
|                     |         |               | 20 mg tadalafil + 10 mg aluzosin (N = 23) | 2                   | 1                             | —                                     | 12                     |
| Pattanaik (2019) [49] | India | RCT           | 5 mg tadalafil (N = 38)      | 1                   | —                             | 1                                     | 6                      |
| Yamazaki (2020) [50] | Japan | Prospective  | 5 mg tadalafil (N = 1393)    | 672                 | 98                            | 130                                   | 72                     |
| Koyama (2018) [51] | Japan | Prospective  | 5 mg tadalafil (N = 58)      | 7                   | 3                             | 4                                     | 4                      |
| Madani (2012) [52] | Iran  | RCT           | 10 mg tadalafil (N = 66)     | 6                   | 6                             | —                                     | 12                     |
|                     |         |               | 5 mg tadalafil + 0.2 mg tamsulosin/4 mg silodosin (N = 167) | 10                 | 8                             | —                                     | 8                      |
| Takeda (2017) [53] | Japan | RCT           | 5 mg tadalafil + ABs \(^4\) (N = 158) | 18                 | 7                             | —                                     | 12                     |
| Goldfischer (2012) [54] | US    | RCT           | 5 mg tadalafil + ABs \(^4\) (N = 158) | 18                 | 7                             | —                                     | 12                     |
| Morgia (2018) [55] | Italy  | RCT           | 5 mg tadalafil (N = 136)     | 8                   | —                             | —                                     | 24                     |
| Dmochowski (2013) [56] | US and Canada | RCT           | 20 mg tadalafil (N = 99)     | 10                 | 2                             | —                                     | 12                     |
| Dell’Atti (2015) [57] | Italy | RCT           | 5 mg tadalafil (N = 56)      | 3                   | 3                             | —                                     | 12                     |
| Matsukawa (2021) [58] | Japan | Prospective  | 5 mg tadalafil (N = 66)      | 7                   | 2                             | —                                     | 48                     |
| Maselli (2011) [59] | Italy  | RCT           | 5 mg tadalafil (N = 28)      | 2                   | 2                             | —                                     | 12                     |

\(^1\)Studies for which countries are unknown. \(^2\)The ten countries are Australia, Austria, Belgium, France, Germany, Greece, Italy, Mexico, the Netherlands, and Poland. \(^3\)Both these studies underwent two phases, namely, a double-blind period followed by an open-label extension phase. \(^4\)ABs here includes uroselective (aluzosin, silodosin, or tamsulosin) and non-uroselective (doxazosin or terazosin).
between 2000 and 2017 showed that patients who received FDC had higher treatment persistence for their hypertension medication than those who received a free-dose combination [69].

Unlike the overall discontinuation rate, the discontinuation rate due to AEs was higher with CT than with tadalafil monotherapy. Although most AEs are self-limiting, they directly affect a patient’s perception of treatment satisfaction. The least wanted undesirable effect was ejaculatory dysfunction (retrograde or diminished ejaculation), which is a well-known side effect of selective ABs [70]. This has previously been shown to be the main factor associated with high satisfaction in the tadalafil only group compared with the PDE5-I combination or tadalafil combination groups (both of which include the use of ABs) [71]. In our study, 9 patients in the CT group (tadalafil + tamsulosin) discontinued due to ejaculatory dysfunction. Interestingly, none received tamsulosin or silodosin before taking the CT (both of which include the use of ABs) [71].

Figure 2: Forest plot illustrating the single study and summary incidence of discontinuation with tadalafil alone or in combination with ABs for LUTS with or without ED. ABs: a-blockers; CI: confidence interval; ED: erectile dysfunction; LUTS: lower urinary tract symptoms.
| Study               | Events | Total | Events per 100 observations | Events | 95%-CI         | Weight (%) |
|---------------------|--------|-------|----------------------------|--------|----------------|------------|
| McVary (2007)       | 5      | 267   |                            | 1.87   | [0.61; 4.32]  | 2.9        |
| Roehrborn (2008)    | 41     | 846   |                            | 4.85   | [3.50; 6.52]  | 3.1        |
| Porst (2009)        | 21     | 466   |                            | 4.51   | [2.81; 6.81]  | 3.1        |
| Porst (2011)        | 3      | 161   |                            | 1.86   | [0.39; 3.35]  | 2.7        |
| Kim (2011)          | 2      | 51    |                            | 3.92   | [0.48; 13.46] | 2.0        |
| Oelke (2012)        | 2      | 171   |                            | 1.17   | [0.14; 4.16]  | 2.7        |
| Egerdie (2012)      | 9      | 406   |                            | 2.22   | [1.02; 4.17]  | 3.0        |
| Yokoyama (2012)     | 12     | 306   |                            | 3.92   | [2.04; 6.75]  | 2.9        |
| Takeda (2012)       | 42     | 678   |                            | 6.21   | [4.51; 8.31]  | 3.1        |
| Takeda (2014)       | 4      | 306   |                            | 1.31   | [0.36; 3.31]  | 2.9        |
| Yang (2019)         | 2      | 51    |                            | 3.92   | [0.48; 13.46] | 2.0        |
| Matsukawa (2019)    | 5      | 105   |                            | 4.76   | [1.56; 10.76] | 2.5        |
| Bechara (2014)      | 1      | 67    |                            | 1.49   | [0.04; 8.04]  | 2.2        |
| Zhang (2018)        | 6      | 363   |                            | 1.65   | [0.61; 3.36]  | 3.0        |
| Bechara (2008)      | 1      | 15    |                            | 6.67   | [0.17; 31.95] | 1.0        |
| Singh (2014)        | 5      | 88    |                            | 5.68   | [1.87; 12.76] | 2.4        |
| Karami (2016)       | 4      | 122   |                            | 3.28   | [0.90; 8.18]  | 2.6        |
| Nagasubramanian (2020) | 4   | 69    |                            | 5.80   | [1.60; 14.18] | 2.2        |
| Lee (2012)          | 3      | 138   |                            | 1.90   | [0.39; 5.45]  | 2.7        |
| Ahn (2020)          | 28     | 97    |                            | 28.87  | [20.11; 38.95]| 2.4        |
| Wada (2020)         | 21     | 155   |                            | 13.35  | [8.59; 19.96] | 2.7        |
| Pinggera (2014)     | 4      | 47    |                            | 8.51   | [2.37; 20.38] | 1.9        |
| Takahashi (2020)    | 8      | 31    |                            | 25.81  | [11.86; 44.61]| 1.5        |
| Matsukawa (2020)    | 4      | 80    |                            | 5.00   | [1.38; 12.31]| 2.3        |
| Amano (2017)        | 1      | 81    |                            | 1.23   | [0.03; 6.69]  | 2.3        |
| Donatucci (2010)    | 22     | 427   |                            | 5.15   | [3.26; 7.70]  | 3.0        |
| Choi (2014)         | 3      | 90    |                            | 3.33   | [0.69; 9.43]  | 2.4        |
| Kang (2012)         | 3      | 84    |                            | 3.57   | [0.74; 10.08] | 2.3        |
| Yoshida (2017)      | 1      | 139   |                            | 0.72   | [0.02; 3.94]  | 2.6        |
| Urakami (2018)      | 7      | 38    |                            | 18.42  | [7.74; 34.33] | 1.7        |
| Takahashi (2016)    | 4      | 35    |                            | 11.43  | [3.20; 26.74] | 1.6        |
| Liguori (2009)      | 3      | 44    |                            | 6.82   | [1.43; 18.66] | 1.8        |
| Yamazaki (2020)     | 98     | 1393  |                            | 7.04   | [5.75; 8.51]  | 3.2        |
| Won (2018)          | 6      | 637   |                            | 0.94   | [0.35; 2.04]  | 3.1        |
| Koyama (2018)       | 3      | 58    |                            | 5.17   | [1.08; 14.38] | 2.1        |
| Madani (2012)       | 6      | 66    |                            | 9.09   | [3.41; 18.74] | 2.1        |
| Takeda (2017)       | 8      | 167   |                            | 4.79   | [2.09; 9.22]  | 2.7        |
| Goldfischer (2012)  | 7      | 158   |                            | 4.43   | [1.80; 8.92]  | 2.7        |
| Dmochowski (2013)   | 2      | 99    |                            | 2.02   | [0.25; 7.11]  | 2.4        |
| Dell'Atti (2015)    | 3      | 56    |                            | 5.36   | [1.12; 14.87] | 2.0        |
| Matsukawa (2021)    | 2      | 66    |                            | 3.03   | [0.37; 10.52] | 2.1        |
| Random effect model | 8742   |       |                            | 4.56   | [3.39; 5.90]  | 100.0      |

**Figure 3:** Continued.
studies investigating once-daily tadalafil, which reported discontinuation rates due to side effects as low as 1% to 5% [72–74].

4.1. Limitations. This study had several limitations which should be mentioned. First, adherence/compliance with a therapeutic regimen or time to discontinuation has previously been identified as a public health issue that may exert a significant impact on clinical outcomes. However, a lack of concrete data makes it impossible to assess this indicator. Second, there were differences in the subjects’ characteristics and demographics, dosing regimen, drug class, study population, entry criteria, study type, and study length, all of which may have led to the heterogeneity encountered between the studies, and may have affected the final results of the study. Therefore, these results should be interpreted with caution. Third, our results are subject to the limitation that the study did not include ABs monotherapy. However, it should be recognized that ABs are only applicable to the

| Study               | Events | Total | Events per 100 observations | Events | 95%-CI | Weight |
|---------------------|--------|-------|-------------------------------|--------|--------|--------|
| Roehrborn (2008)    | 6      | 846   | 0.71 [0.26; 1.54]             | 6.9%   |
| Porst (2009)        | 3      | 466   | 0.64 [0.13; 1.87]             | 6.8%   |
| Porst (2011)        | 1      | 161   | 0.62 [0.02; 3.41]             | 6.3%   |
| Egerdie (2012)      | 4      | 406   | 0.99 [0.27; 2.50]             | 6.8%   |
| Yokoyama (2012)     | 1      | 306   | 0.33 [0.01; 1.81]             | 6.7%   |
| Takeda (2012)       | 7      | 676   | 1.04 [0.42; 2.12]             | 6.9%   |
| Lee (2012)          | 12     | 158   | 7.59 [3.99; 12.89]            | 6.3%   |
| Ahn (2020)          | 10     | 97    | 10.31 [5.06; 18.14]           | 5.9%   |
| Wada (2020)         | 31     | 155   | 20.00 [14.01; 27.17]          | 6.3%   |
| Amano (2017)        | 1      | 81    | 1.23 [0.03; 6.69]             | 5.7%   |
| Donatucci (2010)    | 15     | 427   | 3.51 [1.98; 5.73]             | 6.8%   |
| Choi (2014)         | 5      | 90    | 5.56 [1.83; 12.49]            | 5.8%   |
| Kang (2012)         | 1      | 84    | 1.19 [0.03; 6.46]             | 5.7%   |
| Pattanaik (2019)    | 1      | 38    | 2.63 [0.07; 13.81]            | 4.7%   |
| Yamazaki (2020)     | 130    | 1393  | 9.33 [7.86; 10.98]            | 7.0%   |
| Koyama (2018)       | 4      | 58    | 6.90 [1.91; 16.73]            | 5.3%   |
| Random effect model |        | 5442  | 3.30 [1.53; 5.72]             | 100.0% |

Figure 3: Forest plot illustrating the discontinuation rate due to AEs and no efficacy. (a) AEs, (b) No efficacy. AEs: adverse events; CI: confidence interval.

Table 2: Results of subgroup analysis of the incidence of discontinuation with tadalafil alone or in combination with ABs for LUTS patients with or without ED.

| Items                                | No. of studies | Discontinuation (n) | Index patients (n) | Incidence (%) (95% Cl) | I² (%) |
|--------------------------------------|----------------|---------------------|--------------------|------------------------|--------|
| **Drug regimen**                     |                |                     |                    |                        |        |
| Monotherapy                          | 38             | 1527                | 7686               | 12.16 [9.20, 15.46]    | 97     |
| CT                                   | 10             | 197                 | 1547               | 12.87 [6.59, 20.86]    | 92     |
| **Drug regimen (discontinuation due to AEs)** |            |                     |                    |                        |        |
| Monotherapy                          | 36             | 361                 | 7980               | 4.12 [3.08, 5.30]      | 79     |
| CT                                   | 9              | 57                  | 792                | 6.43 [2.72, 11.59]     | 84     |
| **Study design**                     |                |                     |                    |                        |        |
| Prospective                          | 11             | 791                 | 2164               | 17.53 [10.87, 25.39]   | 97     |
| Retrospective                        | 2              | 118                 | 252                | 46.82 [40.70, 52.99]   | 0      |
| RCT                                  | 31             | 815                 | 6844               | 9.78 [7.66, 12.12]     | 89     |
| **Combination form**                 |                |                     |                    |                        |        |
| FDC                                  | 2              | 108                 | 879                | 24.00 [0.52, 66.34]    | 99     |
| FDC*                                 | 1              | 64                  | 782                | 8.18 [6.36, 10.33]     | —      |
| Free-dose combination                | 8              | 89                  | 695                | 10.62 [5.84, 16.61]    | 81     |

*Result after excluding the only retrospective study in this subset of FDC vs. free-dose combination. ABs: a-blockers; AEs: adverse events; CI: confidence interval; CT: combination therapy; ED: erectile dysfunction; FDC: fixed-dose combination; LUTS: lower urinary tract symptoms; RCT: randomized clinical trial.
treatment of LUTS and not ED, which is a factor in the targeting of comorbid conditions. Finally, because of the inclusion of different study types, we did not perform any analysis of any specific factors that could significantly alter or affect the treatment discontinuation rates. In fact, treatment discontinuation was associated with objective clinical data and provider factors, as well as demographic data and subjective symptoms in patients with LUTS. Thus, a large-scale, prospective, randomized trial should be performed to further investigate the factors influencing treatment discontinuation.

5. Conclusion

The discontinuation rate of tadalafl alone or in combination with ABs for LUTS with or without ED was relatively low and varied according to the study type. Patients treated with CT or monotherapy were similarly likely to abandon treatment. Furthermore, treatment with FDC appeared to have better persistence than the free-dose combination. These data may help guide clinicians in decision-making for drug regimens. At the same time, further studies are required to assess the factors affecting the discontinuation incidence and help develop strategies to reduce their occurrence.

Data Availability

All data generated or analyzed during this study are included in this article (and its Supplementary material files).

Ethical Approval

This retrospective review of patient data did not require ethical approval in accordance with local/national guidelines. Written informed consent from participants was not required in accordance with local/national guidelines.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Research conception and design was performed by Songxi Tang and Qiang Chen. Data acquisition was performed by Qiang Chen and Yinjun Mao. Statistical analysis was performed by Qiang Chen and Yinjun Mao. Data analysis and interpretation was performed by Yinjun Mao and Huiliang Zhou. Drafting of the manuscript was performed by Qiang Chen and Yinjun Mao. Critical revision of the manuscript was performed by Songxi Tang and Huiliang Zhou. Supervision was performed by Songxi Tang. Approval of the final manuscript was given by all authors. Qiang Chen and Yinjun Mao contributed equally to this work.

Supplementary Materials

Table S1: PRISMA 2020 checklist. Table S2: Search strategy. Table S3: Newcastle-Ottawa Scale assessment results of included observational studies. Table S4: Risk of bias of the RCTs calculated with the Cochrane risk of bias assessment tool. Figure S1: Forest plot illustrating subgroup analysis of the incidence of discontinuation with tadalafl alone or in combination with ABs for LUTS with or without ED. (A) Drug regimen, (B) Drug regimen (discontinuation due to AEs), (C) Study design, (D) Combination form. ABs: a-blockers; AEs: adverse events; CI: confidence interval; CT: combination therapy; ED: erectile dysfunction; FDC: fixed-dose combination; LUTS: lower urinary tract symptoms; RCT: randomized clinical trial. Figure S2: Cumulative meta-analysis of the discontinuation rate. CI: confidence interval. Figure S3: Sensitivity analysis of the discontinuation rate. CI: confidence interval. (Supplementary Materials)

References

[1] M. Gacci, I. Eardley, F. Giuliani et al., “Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia,” *European Urology*, vol. 60, no. 4, pp. 809–825, 2011.

[2] M. Oelke, A. Bachmann, A. Descarreaux et al., “EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction,” *European Urology*, vol. 64, no. 1, pp. 118–140, 2013.

[3] K. T. McVary, C. G. Roehrborn, A. L. Avins et al., “Update on AUA guideline on the management of benign prostatic hyperplasia,” *The Journal of Urology*, vol. 185, no. 5, pp. 1793–1803, 2011.

[4] V. Mironov, A. Sessa, F. Giuliani, R. Berges, M. Kirby, and I. Moncada, “Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events,” *International Journal of Clinical Practice*, vol. 65, no. 9, pp. 1005–1013, 2011.

[5] C. G. Roehrborn, K. T. McVary, A. Elion-Mboussa, and L. Viktrup, “Tadalafl administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study,” *The Journal of Urology*, vol. 180, no. 4, pp. 1228–1234, 2008.

[6] M. Takeda, O. Yokoyama, S. W. Lee, M. Murakami, Y. Morisaki, and L. Viktrup, “Tadalafl 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea,” *International Journal of Urology*, vol. 21, no. 7, pp. 670–675, 2014.

[7] S. Filippi, A. Morelli, P. Sandner et al., “Characterization and functional role of androgen-dependent PDE5 activity in the bladder,” *Endocrinology*, vol. 148, no. 3, pp. 1019–1029, 2007.

[8] B. Fibbi, A. Morelli, L. Vignozzi et al., “Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract,” *The Journal of Sexual Medicine*, vol. 7, no. 1, pp. 59–69, 2010.

[9] M. Gacci, G. Corona, M. Salvi et al., “A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia,” *European Urology*, vol. 61, no. 5, pp. 994–1003, 2012.

[10] Z. Hakimi, M. Johnson, I. Nazir, B. Blak, and I. A. Odeyemi, “Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic
hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data,” *Current Medical Research and Opinion*, vol. 31, no. 1, pp. 43–50, 2015.

[11] A. Wagg, G. Compion, A. Fahey, and E. Siddiqui, “Persistence with prescribed antimicrobial therapy for overactive bladder: a UK experience,” *BJU International*, vol. 110, no. 11, pp. 1767–1774, 2012.

[12] “The study protocol,” 2022, https://inplasy.com/wp-content/uploads/2022/06/INPLASY-Protocol-3532.pdf.

[13] M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” *BMJ*, vol. 372, p. n71, 2021.

[14] M. Borenstein, L. V. Hedges, J. P. Higgins, and M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., “The PRISMA statement,” 2022, https://inplasy.com/wp-content/uploads/2022/06/INPLASY-Protocol-3532.pdf.

[15] J. J. Barendregt, S. A. Doi, Y. Y. Lee, R. E. Norman, and T. Vos, “Meta-analysis of prevalence,” *Journal of Epidemiology & Community Health*, vol. 67, no. 11, pp. 974–978, 2013.

[16] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analyses,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[17] J. P. T. Higgins, S. G. Thompson, and D. J. Spiegelhalter, “A re-evaluation of random-effects meta-analysis,” *Journal of the Royal Statistical Society: Series A*, vol. 172, no. 1, pp. 137–159, 2009.

[18] K. T. McVary, C. G. Roehrborn, J. C. Caminitesky et al., “Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia,” *The Journal of Urology*, vol. 177, no. 4, pp. 1401–1407, 2007.

[19] H. Porst, K. T. McVary, F. Montorsi et al., “Effects of once-daily tadalafl on erectile function in men with erectile dysfunction and symptoms of benign prostatic hyperplasia,” *European Urology*, vol. 56, no. 4, pp. 727–736, 2009.

[20] H. Porst, E. D. Kim, A. R. Casabe et al., “Efficacy and safety of tadalafl once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial,” *European Urology*, vol. 60, no. 5, pp. 1105–1113, 2011.

[21] S. C. Kim, J. K. Park, S. W. Kim et al., “Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control,” *Lower Urinary Tract Symptoms*, vol. 3, no. 2, pp. 86–93, 2011.

[22] M. Oelke, F. Giuliani, V. Miron, L. Xu, D. Cox, and L. Viktrup, “Monotherapy with tadalafl or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial,” *European Urology*, vol. 61, no. 5, pp. 917–925, 2012.

[23] R. B. Egerdie, S. Auerbach, C. G. Roehrborn et al., “Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study,” *The Journal of Sexual Medicine*, vol. 9, no. 1, pp. 271–281, 2012.

[24] O. Yokoyama, M. Yoshida, S. C. Kim et al., “Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men,” *International Journal of Urology*, vol. 20, no. 2, pp. 193–201, 2013.

[25] M. Takeda, O. Nishizawa, T. Imaoka, Y. Morisaki, and L. Viktrup, “Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia: results from a 12-week placebo-controlled dose-finding study with a 42-week open-label extension,” *Lower Urinary Tract Symptoms*, vol. 4, no. 3, pp. 110–119, 2012.

[26] D. Y. Yang, H. C. Jeong, K. Ko et al., “Effect of tadalafl 5 mg on post-micturition dribble in men with lower urinary tract symptoms: a multicentre, double-blind, randomized, placebo-controlled trial,” *BJU International*, vol. 124, no. 5, pp. 862–869, 2019.

[27] Y. Matsukawa, S. Takai, T. Majima et al., “Objective impacts of tadalafl on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study,” *World Journal of Urology*, vol. 37, no. 5, pp. 867–872, 2019.

[28] A. Bechara, A. Casabe, G. Rodriguez Baigorri, and C. Cobreros, “Effectiveness of tadalafl 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study,” *The Journal of Sexual Medicine*, vol. 11, no. 2, pp. 498–505, 2014.

[29] Z. Zhang, H. Li, X. Zhang et al., “Efficacy and safety of tadalafl 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: a phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study,” *International Journal of Urology*, vol. 26, no. 2, pp. 192–200, 2019.

[30] A. Bechara, S. Romano, A. Casabe et al., “Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafl in the treatment of LUTS/BPH. Pilot study,” *The Journal of Sexual Medicine*, vol. 5, no. 9, pp. 2170–2178, 2008.

[31] D. V. Singh, U. K. Mete, A. K. Mandal, and S. K. Singh, “A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafl vs. tamsulosin or tadalafl alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia,” *The Journal of Sexual Medicine*, vol. 11, no. 1, pp. 187–196, 2014.

[32] H. Karami, A. Hassanzadeh-Hadad, and M. Fallah-Karkan, “Comparing monotherapy with tadalafl or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial,” *Urology Journal*, vol. 13, no. 6, pp. 2920–2926, 2016.

[33] S. W. Kim, N. C. Park, S. W. Lee et al., “Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafl for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial,” *The Journal of Sexual Medicine*, vol. 14, no. 8, pp. 1018–1027, 2017.

[34] S. Nagasubramanian, N. T. John, B. Antonisamy et al., “Tamsulosin and placebo vs tamsulosin and tadalafl in male lower urinary tract symptoms: a double-blinded, randomised controlled trial,” *BJU International*, vol. 125, no. 5, pp. 718–724, 2020.

[35] J. Y. Lee, S. Y. Park, T. Y. Jeong et al., “Combined tadalafl and alpha-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study,” *Journal of Andrology*, vol. 33, no. 3, pp. 397–403, 2012.

[36] S. T. Ahn, D. H. Lee, H. G. Jeong et al., “Treatment persistence with a fixed-dose combination of tadalafl (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in
patients with benign prostatic hyperplasia and erectile dysfunction,” *Investig Clin Urol*, vol. 61, no. 1, pp. 81–87, 2020.

[37] N. Wada, D. Kikuchi, J. Tateoka et al., “Persistence rate with tadalafil for treatment of male lower urinary tract symptoms,” *Urologia Internationalis*, vol. 104, no. 6, pp. 373–377, 2020.

[38] G. M. Pinggera, F. Frauscher, D. A. Paduch et al., “Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial,” *Urology*, vol. 84, no. 2, pp. 412–420, 2014.

[39] R. Takahashi, Y. Sumino, M. Miyazato et al., “Tadalafil improves nocturia and nocturia-related quality of life in patients with benign prostatic hyperplasia (KYU-pro study),” *Urologia Internationalis*, vol. 104, no. 7-8, pp. 587–593, 2020.

[40] Y. Matsukawa, Y. Kanada, S. Takai et al., “Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction,” *The Aging Male*, vol. 23, no. 5, pp. 641–647, 2020.

[41] T. Amano, C. Earle, T. Imao, Y. Matsumoto, and T. Kishikage, “Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia,” *The Aging Male*, vol. 21, no. 1, pp. 77–82, 2018.

[42] C. F. Donatucci, G. B. Brock, E. R. Goldfischer et al., “Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study,” *BJU International*, vol. 107, no. 7, pp. 1110–1116, 2011.

[43] H. Choi, J. H. Kim, J. S. Shim et al., “Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms,” *International Journal of Impotence Research*, vol. 27, no. 1, pp. 33–37, 2015.

[44] D. H. Kang, J. Y. Lee, J. H. Chung et al., “Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction,” *International Journal of Clinical Practice*, vol. 66, no. 8, pp. 813–820, 2012.

[45] M. Yoshida, H. Origasa, and N. Seki, “Comparison of silodosin versus tadalafil in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia,” *Lower Urinary Tract Symptoms*, vol. 9, no. 3, pp. 176–186, 2017.

[46] S. Urakami, K. Ogawa, S. Oka et al., “Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1-adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: a randomized pilot trial comparing tadalafil and solifenacin,” *Lower Urinary Tract Symptoms*, vol. 11, no. 3, pp. 109–114, 2019.

[47] R. Takahashi, M. Miyazato, H. Nishii et al., “Tadalafil improves symptoms, erectile function and quality of life in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (KYU-pro study),” *Lower Urinary Tract Symptoms*, vol. 10, no. 1, pp. 76–83, 2018.

[48] G. Liguori, C. Trombetta, G. De Giorgi et al., “Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction,” Preliminary report,” *The Journal of Sexual Medicine*, vol. 6, no. 2, pp. 544–552, 2009.

[49] S. Pattanaik, H. S. Sandhu, R. S. Mavuduru, S. K. Singh, and A. K. Mandal, “Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: a randomized double blind placebo controlled cross-over study,” *Indian Journal of Urology*, vol. 35, no. 1, pp. 25–33, 2019.

[50] H. Yamazaki, N. Tsujimoto, M. Koyanagi, M. C. Katoh, K. Tajima, and M. Komori, “Real-World safety and effectiveness of tadalafil in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a Japanese post-marketing surveillance study,” *Prognostic and Observational Research*, vol. 11, pp. 45–54, 2020.

[51] J. Koyama, Y. Kaiho, Y. Kawasaki et al., “Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms,” *BJU International*, vol. 123, no. 1, pp. 124–129, 2019.

[52] A. H. Madani, A. Afsharimoghadam, A. Roushani, A. Farzan, A. Asadalollahzade, and M. Shakhiba, “Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication,” *International Brazilian Journal of Urology*, vol. 38, no. 1, pp. 33–39, 2012.

[53] M. Takeda, O. Yokoyama, M. Yoshida et al., “Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized, placebo-controlled, cross-over study,” *International Journal of Urology*, vol. 24, no. 7, pp. 539–547, 2017.

[54] E. Goldfischer, J. J. Kowalczyk, W. R. Clark et al., “Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial,” *Urology*, vol. 79, no. 4, pp. 875–882, 2012.

[55] G. Morgia, G. Vespiasani, R. M. Pareo et al., “Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study),” *BJU International*, vol. 122, no. 2, pp. 317–325, 2018.

[56] R. Dmochowski, C. Roehrborn, S. Klise, L. Xu, J. Kaminetsky, and S. Kraus, “Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial,” *The Journal of Urology*, vol. 189, no. 1, pp. S135–S140, 2013.

[57] L. Dell’Atri, “Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients,” *European Review for Medical and Pharmacological Sciences*, vol. 19, no. 9, pp. 1559–1563, 2015.

[58] Y. Matsukawa, T. Majima, Y. Funahashi et al., “Effects of tadalafil versus silodosin on voiding function in male patients with non-neurogenic detrusor underactivity: a comparative study using propensity score matching,” *International Journal of Urology*, vol. 28, no. 4, pp. 411–416, 2021.

[59] G. Maselli, L. Bergamasco, V. Silvestri, L. Guala, G. Pace, and C. Vicentini, “Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study,” *International Journal of Urology*, vol. 18, no. 7, pp. 515–520, 2011.

[60] M. Kirby, C. Chapple, G. Jackson et al., “Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis,” *International Journal of Clinical Practice*, vol. 67, no. 7, pp. 606–618, 2013.

[61] H. J. Park, “The role of the urologist in men’s health,” *The World Journal of Men’s Health*, vol. 35, no. 2, pp. 57–58, 2017.
[62] T. M. Shiovitz, E. E. Bain, D. J. McCann et al., "Mitigating the effects of nonadherence in clinical trials," *Journal of Clinical Pharmacology*, vol. 56, no. 9, pp. 1151–1164, 2016.

[63] J. S. Koh, K. J. Cho, H. S. Kim, and J. C. Kim, "Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia," *International Journal of Clinical Practice*, vol. 68, no. 2, pp. 197–202, 2014.

[64] S. Madersbacher, M. Marszalek, J. Lackner, P. Berger, and G. Schatzl, "The long-term outcome of medical therapy for BPH," *European Urology*, vol. 51, no. 6, pp. 1522–1533, 2007.

[65] A. Sebastianelli, P. Spatafora, J. Frizzi et al., "Tadalafil 5 mg alone or in combination with tamsulosin 0.4 mg for the management of men with lower urinary tract symptoms and erectile dysfunction: results of a prospective observational trial," *Journal of Clinical Medicine*, vol. 8, no. 8, p. 1126, 2019.

[66] F. Pan, M. E. Chernow, and A. M. Fendrick, "Impact of fixed-dose combination drugs on adherence to prescription medications," *Journal of General Internal Medicine*, vol. 23, no. 5, pp. 611–614, 2008.

[67] M. Landeira, A. M. Mora Blázquez, R. Martins de Almeida, P. J. O. Covernton, J. Medina-Polo, and A. A. Montero, "A retrospective analysis comparing persistence and adherence to treatment with free- vs fixed-dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain," *International Journal of Clinical Practice*, vol. 74, no. 11, pp. 1280–1290, 2020.

[68] M. J. Drake, S. Bowditch, E. Arbe et al., "A retrospective study of treatment persistence and adherence to alpha-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in The Netherlands," *BMC Urology*, vol. 17, no. 1, p. 36, 2017.

[69] L. P. Du, Z. W. Cheng, Y. X. Zhang, Y. Li, and D. Mei, "The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis," *Journal of Clinical Hypertension*, vol. 20, no. 5, pp. 902–907, 2018.

[70] I. A. Abdel-Hamid and O. I. Ali, "Delayed ejaculation: pathophysiology, diagnosis, and treatment," *The World Journal of Men’s Health*, vol. 36, no. 1, pp. 22–40, 2018.

[71] L. K. Lee, A. Goren, N. N. Boytsov, C. F. Donatucci, and K. T. McVary, "Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations," *Patient Preference and Adherence*, vol. 10, pp. 1205–1215, 2016.

[72] J. E. Won, J. Y. Chu, H. C. Choi, Y. Chen, H. J. Park, and H. J. Duenas, "Safety and effectiveness of once-daily tadalafil (5 mg) therapy in Korean men with benign prostatic hyperplasia/lower urinary tract symptoms in a real-world clinical setting: results from a post-marketing surveillance study," *The World Journal of Men’s Health*, vol. 36, no. 2, pp. 161–170, 2018.

[73] J. Rajfer, P. J. Aliotta, C. P. Steidle, W. P. Fitch, Y. Zhao, and A. Yu, "Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US," *International Journal of Impotence Research*, vol. 19, no. 1, pp. 95–103, 2007.

[74] H. Porst, J. Rajfer, A. Casabe et al., "Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction," *The Journal of Sexual Medicine*, vol. 5, no. 9, pp. 2160–2169, 2008.